Showing results (111-120 of 242) with videos related to
Sort By:
Pageof 25
Cancer Research|December 15, 1994
Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell lineP Naredi, D D Heath, R E Enns, et al.Cancer Treatment Reports|September 1, 1982
High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose scheduleT N Campbell, S B Howell, C Pfeifle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1988
Phase I/pharmacokinetic study of thioguanine administered as a 48-hour continuous intraperitoneal infusionS Zimm, S M Cleary, C N Horton, et al.Molecular Pharmacology|November 28, 2001
Identification of genes that mediate sensitivity to cisplatinH Niedner, R Christen, X Lin, et al.The Journal of Clinical Investigation|March 1, 1995
Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cellsP Naredi, D D Heath, R E Enns, et al.Cancer Drug Delivery|January 1, 1985
Maintenance of peritoneal catheter function by the intraperitoneal administration of 32% dextran 70C E Pfeifle, S B Howell, I S Abramson, et al.Molecular Pharmacology|January 1, 1997
Role of determinants of cadmium sensitivity in the tolerance of Schizosaccharomyces pombe to cisplatinP Perego, J Vande Weghe, D W Ow, et al.Cancer Research|March 1, 1980
Antitumor activity of L-canavanine against L1210 murine leukemiaM H Green, T L Brooks, J Mendelsohn, et al.Molecular Pharmacology|November 28, 2000
p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxideX Lin, K Ramamurthi, M Mishima, et al.Cancer Chemotherapy and Pharmacology|January 1, 1994
Enhancement of the cytotoxicity of cisplatin by the cholecystokinin antagonist MK-329 in a human pancreatic cancer cell lineR Jamshidipour, E B Pinho, D K Hom, et al.Pageof 25